Equities analysts predict that Jounce Therapeutics Inc (NASDAQ:JNCE) will announce $12.80 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Jounce Therapeutics’ earnings, with the lowest sales estimate coming in at $11.20 million and the highest estimate coming in at $15.50 million. Jounce Therapeutics reported sales of $18.08 million in the same quarter last year, which indicates a negative year over year growth rate of 29.2%. The firm is expected to issue its next quarterly earnings results before the market opens on Tuesday, November 13th.
On average, analysts expect that Jounce Therapeutics will report full year sales of $56.73 million for the current financial year, with estimates ranging from $52.96 million to $61.57 million. For the next year, analysts forecast that the firm will report sales of $65.05 million, with estimates ranging from $43.00 million to $86.00 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings results on Friday, August 10th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.23. Jounce Therapeutics had a negative net margin of 50.54% and a negative return on equity of 23.27%. The business had revenue of $19.38 million for the quarter, compared to analysts’ expectations of $12.47 million.
Several equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research report on Tuesday, October 16th. Raymond James reduced their price target on shares of Jounce Therapeutics from $13.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 23rd. HC Wainwright set a $13.00 price target on shares of Jounce Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 13th. JPMorgan Chase & Co. reduced their price target on shares of Jounce Therapeutics from $12.00 to $10.00 and set a “hold” rating on the stock in a research report on Friday, August 10th. Finally, ValuEngine raised shares of Jounce Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $11.92.
Several hedge funds have recently modified their holdings of JNCE. NumerixS Investment Technologies Inc bought a new position in Jounce Therapeutics in the second quarter worth about $132,000. Creative Planning bought a new position in Jounce Therapeutics in the third quarter worth about $143,000. Bank of America Corp DE lifted its holdings in Jounce Therapeutics by 243.4% in the second quarter. Bank of America Corp DE now owns 28,607 shares of the company’s stock worth $219,000 after acquiring an additional 20,276 shares during the last quarter. Trexquant Investment LP bought a new position in Jounce Therapeutics in the third quarter worth about $216,000. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Jounce Therapeutics by 20.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 47,951 shares of the company’s stock worth $368,000 after acquiring an additional 8,103 shares during the last quarter. 84.49% of the stock is currently owned by institutional investors and hedge funds.
Shares of JNCE stock opened at $4.81 on Friday. Jounce Therapeutics has a one year low of $4.03 and a one year high of $29.25. The stock has a market cap of $174.23 million, a PE ratio of -8.44 and a beta of 4.97.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
Read More: Why do companies engage in swaps?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.